Loading…
← CockpitCompetitor Analysis › AMRX Amneal Pharmaceuticals, Inc. Class AOpen in the cockpit ↗

Amneal Pharmaceuticals, Inc. Class AAMRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Generic-drug maker also developing specialty drugs for Parkinson's disease and other conditions.

Momentum leader 96
Mkt cap
$7.62B
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$77.1M
20-day average traded
Fwd P/E
19.2×
forward earnings
ROIC−WACC
+1.2 pp
WACC 9.6%
Hurdle
+8 pp
Req g minus delivered
Next earnings
100 days
26 Feb 2027
Close · USD$21.88
1D+3.6%
1W+0.8%
1M+10.3%
3M+22.2%
6M+78.9%
YTD+73.7%
1Y+89.0%
ATR %3.5%
Beta0.66
52w lowhigh1.1% off high

What Amneal Pharmaceuticals does

Generic-drug maker also developing specialty drugs for Parkinson's disease and other conditions.

Sells most products to three big drug wholesalers that supply US pharmacies, so a few buyers set terms on generics, where price competition is intense. To offset that, it has been adding branded specialty drugs, such as Crexont, approved in 2024, and biosimilars, copies of biologic medicines, from partners.

Products and services

  • Generic drugs
  • Crexont/IPX203 (Parkinson's)
  • Injectables/complex generics

Customers

  • Pharmacies/distributors
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics & specialty
  • Generics manufacturing and specialty…

What could go right

  • Crexont launch in Parkinson's disease
  • New generic approvals from a large filing pipeline

What could go wrong

  • Generic price erosion
  • Execution risk scaling the specialty business

Moat: narrow (scale, cost advantage). Vertically integrated US generics manufacturing scale, with a smaller specialty franchise for differentiation.

Headquarters: Bridgewater, New Jersey, United States · Founded: 2002 · Employees: 8,500

Named competitors

Amneal Pharmaceuticals at a glance

Size Amneal Pharmaceuticals (AMRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.62B, the 907th largest of 3,085 United States companies the cockpit tracks. Shares closed at $21.88 on 18 Nov 2026.

Performance Over six months the shares gained 78.9%, against -0.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 8.9% over the last twelve months (peer median +13.9%); the operating margin is 16.4% (peer median 13.8%).

Valuation It trades at 19.2× forward earnings against a peer median of 21.9× (8th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.2 points above its cost of capital (9.6% WACC).

Short interest Short interest is 3.3% of the free float (30 Oct 2026).

Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026AMRX 176Peer median 101
Six months, rebased to 100: Amneal Pharmaceuticals against the median of its 20 peers (local-currency closes).

Amneal Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.20B$3.02B$2.79B$2.39B$2.21B
Revenue growth—+8%+17%+8%—
Gross profit$1.29B$1.14B$1.02B$857M$796M
EBITDA$719M$647M$589M$492M$441M
Net income$133M$72.1M-$117M-$84.0M-$130M
Free cash flow$30.9M$241M$235M$136M$14.6M
Capital expenditure$242M$114M$75.0M$69.2M$90.6M
Total debt$3.28B$2.69B$2.59B$2.75B$2.85B

Quarterly statements and history in the cockpit →

Amneal Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%600196GRFKNSACORTALKS4528ALK-BGLENMARK002821CYTKIBRXBANBRYTM9926PTGX4151PRAXAMRX6-month return →1-month return →
Up and to the right = strong over both horizons. Amneal Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×600196GRFKNSACORT002821PTGXAMRXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Amneal Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%600196GRFKNSACORTALKS4528ALK-BGLENMARK601607PTGX000963ALKEMAMRXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Amneal Pharmaceuticals is the large dot.

Amneal Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (AMRX vs TEVA vs VTRS vs AMPH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Amneal Pharmaceuticals AMRX$7.62B+79%+9%16%19.2×17.2%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%
Amphastar Pharmaceuticals AMPH$1.27B+64%+3%19%9.1×2.5%

How Amneal Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Amneal Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureAMRXPeer medianRank in peer set
1-month return+10.3%+1.7%6th highest of 21
6-month return+78.9%-0.4%highest of 21
Distance from 52-week high-1.1%-13.9%highest of 21
Revenue growth (TTM)+8.9%+13.9%9th lowest of 21
Operating margin16.4%13.8%9th highest of 20
Forward P/E19.2×21.9×8th cheapest of 15
Growth the price implies (Req g, 7 yrs)17.2%7.3%6th most demanding of 14
Growth delivered (Del g)+8.7%+9.4%6th lowest of 14
Hurdle (Req g minus delivered)+8.5 pp-3.7 pp4th most demanding of 14
ROIC minus cost of capital+1.2 pp+1.7 pp8th lowest of 19
EV / EBITDA15.1×23.1×4th cheapest of 12
Net debt / EBITDA4.3×-0.3×3rd most indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%14.8×2.9%+6.6%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%

Questions

Who are Amneal Pharmaceuticals's main competitors?
Named competitors: Teva Pharmaceutical (TEVA), Viatris (VTRS), Amphastar Pharmaceuticals (AMPH). The cockpit's measured peer set (industry) also includes Shanghai Fosun Pharmaceutical (Group) (600196.SS), Grifols (GRF.MC), Kiniksa Pharmaceuticals International (KNSA), Corcept Therapeutics (CORT), Alkermes Public (ALKS), ONO Pharmaceutical (4528.T).
Is Amneal Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 19.2× against a peer median of 21.9×, 8th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Amneal Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +78.9% against -0.4% for the median peer; over one year +89.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.